Venus Remedies has received its first patent from Mexico for ‘Vancoplus’, a novel antibiotic formulation to Combat Methicillin Resistant Staphylococcus Aureus (MRSA) infections. The patent has been granted from the Mexico Patent office and is valid till February 2026.
Receiving a paten grant from Mexico for the research product Vancoplus at this point in time when the frequency of MRSA strains is growing high (50-85%) in Mexico, is a great achievement for the company. Vancoplus will prove to be the best known remedy to control MRSA, VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria in a situation wherein around 3 to 6 percent of the population carries the community form of MRSA.
As per the CDC reports published in the Journal of the American Medical Association in 2010, MRSA infections are constantly on the rise in the community and resistance against antibiotics with nearly 48% of S. aureus isolates were resistant to oxacillin (MRSA), and 49% were resistant to levofloxacin; 33% of Enterococcus faecium isolates were resistant to yancomycin and so on.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
